Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
CMND
#5225
Clearmind Medicine Inc. Common Shares
1.1
3
-0.88%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-0.88%
Aylık değişim
-56.70%
6 aylık değişim
+10.78%
Yıllık değişim
-8.13%
Önceki kapanış
1.1
4
Open
1.1
3
Bid
Ask
Low
1.1
3
High
1.1
3
Hacim
2
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
CMND
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
Q4, 25
TTM
Key stats
Total common shares outstanding
106.63 K
158.08 K
—
Valuation ratios
Enterprise value
148.22 K
125.75 K
—
Price to earnings ratio
—
—
—
Price to sales ratio
—
—
—
Price to cash flow ratio
—
—
—
Price to book ratio
—
—
—
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
—
—
—
Return on equity %
—
—
—
Return on invested capital %
—
—
—
Gross margin %
—
—
—
Operating margin %
—
—
—
EBITDA margin %
—
—
—
Net margin %
—
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
—
—
—
Inventory turnover
—
—
—
Asset turnover
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
—
—
—
Net current asset value per share
—
—
—
Tangible book value per share
—
—
—
Working capital per share
—
—
—
Book value per share
—
—
—
Haberler
クリアマインド・メディシン社の株価、フェーズI/IIa試験の安全性データ更新後に下落
Clearmind Medicine stock falls after Phase I/IIa trial safety update
クリアマインド社、アルコール使用障害薬の試験で良好な安全性結果を報告
クリアマインド、アルコール使用障害治療試験で良好な安全性データを報告
Clearmind reports positive safety results in AUD drug trial
Clearmind reports positive safety data from AUD treatment trial
クリアマインド・メディシン株、ポリライゾンの経鼻投与技術提携で急騰
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal
クリアマインド、MEAIの鼻腔内製剤開発でポリライゾンと提携
Clearmind partners with Polyrizon to develop intranasal MEAI formulation
ポリリゾン、クリアマインドのMEAI薬剤の経鼻製剤開発へ
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug